Hepatitis B infection control in Colombian amazon

Background: Hepatitis B virus (HBV) infection is highly endemic in the Colombian Amazon basin. In Colombia, the universal hepatitis B vaccination in that area has been active since 1993. The program targets children aged under five years. Newborns receive at least three doses, and in 2001, HBV vacci...

Full description

Autores:
Garcia, Diego
Porras, Alexandra
Rico Mendoza, Alejadro
Alvis, Nelson
Cristina Navas, Maria
De La Hoz, Fernando
De Neira, Marlen
Osorio, Elkin
Fernando Valderrama, José
Tipo de recurso:
Article of journal
Fecha de publicación:
2017
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/4718
Acceso en línea:
https://hdl.handle.net/11323/4718
https://repositorio.cuc.edu.co/
Palabra clave:
Hepatitis B
Prevalence
Effectiveness of HBV birth dose
Colombia
Predominio
Eficacia de la dosis de nacimiento del VHB
Rights
openAccess
License
Attribution-NonCommercial-ShareAlike 4.0 International
id RCUC2_65fcc083eae430c994c2748cf67960e5
oai_identifier_str oai:repositorio.cuc.edu.co:11323/4718
network_acronym_str RCUC2
network_name_str REDICUC - Repositorio CUC
repository_id_str
dc.title.spa.fl_str_mv Hepatitis B infection control in Colombian amazon
dc.title.translated.spa.fl_str_mv Control de la infección por hepatitis B en la amazonia colombiana.
title Hepatitis B infection control in Colombian amazon
spellingShingle Hepatitis B infection control in Colombian amazon
Hepatitis B
Prevalence
Effectiveness of HBV birth dose
Colombia
Predominio
Eficacia de la dosis de nacimiento del VHB
title_short Hepatitis B infection control in Colombian amazon
title_full Hepatitis B infection control in Colombian amazon
title_fullStr Hepatitis B infection control in Colombian amazon
title_full_unstemmed Hepatitis B infection control in Colombian amazon
title_sort Hepatitis B infection control in Colombian amazon
dc.creator.fl_str_mv Garcia, Diego
Porras, Alexandra
Rico Mendoza, Alejadro
Alvis, Nelson
Cristina Navas, Maria
De La Hoz, Fernando
De Neira, Marlen
Osorio, Elkin
Fernando Valderrama, José
dc.contributor.author.spa.fl_str_mv Garcia, Diego
Porras, Alexandra
Rico Mendoza, Alejadro
Alvis, Nelson
Cristina Navas, Maria
De La Hoz, Fernando
De Neira, Marlen
Osorio, Elkin
Fernando Valderrama, José
dc.subject.spa.fl_str_mv Hepatitis B
Prevalence
Effectiveness of HBV birth dose
Colombia
Predominio
Eficacia de la dosis de nacimiento del VHB
topic Hepatitis B
Prevalence
Effectiveness of HBV birth dose
Colombia
Predominio
Eficacia de la dosis de nacimiento del VHB
description Background: Hepatitis B virus (HBV) infection is highly endemic in the Colombian Amazon basin. In Colombia, the universal hepatitis B vaccination in that area has been active since 1993. The program targets children aged under five years. Newborns receive at least three doses, and in 2001, HBV vaccine birth dose was included. This study aimed to evaluate the advances on HBV control in the Colombian Amazon. Methods: A population-based cross-sectional study was conducted in children less than 11 years old in rural areas of the Colombian Amazon, in order to assess the current levels of HBV prevalence and evaluate the effectiveness of HBV vaccination. Participants were selected from villages scattered along the Amazon, Putumayo and Loretoyaco Rivers. Blood samples were taken from children. All the samples were examined for surface antigen (HBsAg) and IgG antibodies against core antigen (AntiHBc) of HBV. Data on HBV vaccination status and other risk factors were also collected. Results: Blood samples from 1275 children were included in the study. The positivity for IgG AntiHBC and HBsAg was 3.8% and 0.5%, respectively. It was observed that receiving a dose of HBV vaccine within 48 h after birth decreased the risk of HBV infection and carriage by 95%. Being born to an AntiHBc positive mother increased 8 times the risk of HBV infection (OR = 7.8 CI 95% 3.3–10.2) and 7 times the risk of HBsAg carriage (OR = 6.6 CI 95% 2.1–10.1). Conclusion: The prevalence of HBV infection and HBsAg carriage continues to decrease among children living in the Colombian Amazon. The high protective effectiveness of an HBV birth does suggest that perinatal transmission is important in endemic areas of Latin America, an aspect that has not been fully studied in the region.
publishDate 2017
dc.date.issued.none.fl_str_mv 2017-11-05
dc.date.accessioned.none.fl_str_mv 2019-05-27T14:12:24Z
dc.date.available.none.fl_str_mv 2019-05-27T14:12:24Z
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
format http://purl.org/coar/resource_type/c_6501
status_str acceptedVersion
dc.identifier.uri.spa.fl_str_mv https://hdl.handle.net/11323/4718
dc.identifier.instname.spa.fl_str_mv Corporación Universidad de la Costa
dc.identifier.reponame.spa.fl_str_mv REDICUC - Repositorio CUC
dc.identifier.repourl.spa.fl_str_mv https://repositorio.cuc.edu.co/
url https://hdl.handle.net/11323/4718
https://repositorio.cuc.edu.co/
identifier_str_mv Corporación Universidad de la Costa
REDICUC - Repositorio CUC
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.references.spa.fl_str_mv [1] Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386 (10003):1546–55. [2] Díez-Padrisa N, Castellanos LG, PAHO Viral Hepatitis Working Group. Viral hepatitis in Latin America and the Caribbean: a public health challenge. Rev Panam Salud Publica 2013;34(4):275–81. [3] Bensabath G, Hadler SC, Soares MC, Fields H, Dias LB, Popper H, et al. Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin. JAMA 1987;258(4):479–83. [4] Cabezas-Sánchez C, Trujillo-Villarroel O, Zavaleta-Cortijo C, Culqui-Lévano D, Suarez-Jara M, Cueva-Maza N, et al. Prevalencia de la infección por el virus de hepatitis B en niños menores de 5 años de comunidades indígenas de la Amazonía peruana posterior a intervenciones mediante inmunización. Rev Perú med exp salud publica 2014;31(2):204–10. Available in: <http://www. scielo.org.pe/scielo.php?pid=S1726-46342014000200003&script=sci_arttext> [Consulted in March 17, 2017]. [5] Martínez M, De La Hoz F. Estudio de seroprevalencia y factores de riesgo de infección con el virus de la hepatitis B en los ribereños del río Putumayo, Colombia, 1990–1991. Biomedica 1994;14(suppl 1):51. [6] Van Damme P. Long-term protection after hepatitis B vaccine. J Infect Dis 2016;214(1):1–3. [7] Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunization program. BMC Infect Dis 2014;14:7. [8] Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 2012;16(2):e82–8. [9] Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis 2009;200(1):39–47. [10] Wilson N, Ruff TA, Rana BJ, Leydon J, Locarnini S. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu. Vaccine 2000;18(26):3059–66. [11] World Health Organization. WHO guidelines on hand hygiene in health care. Ginebra: World Health Organization; 2009. Available in: <http://apps.who.int/ iris/bitstream/10665/44102/1/9789241597906_eng.pdf> [Consulted: March 17, 2017]. [12] Ropero AM, Danovaro-Holliday MC, Andrus JK. Progress in vaccination against hepatitis B in the Americas. J Clin Virol 2005;34(suppl 2):S14–9. [13] Braga WS, Castilho Mda C, Borges FG, Martinho AC, Rodrigues IS, Azevedo EP, et al. Prevalence of hepatitis B virus infection and carriage after nineteen years of vaccination program in the Western Brazilian Amazon. Rev Soc Bras Med Trop 2012;45(1):13–7. [14] de la Hoz F, Perez L, de Neira M, Hall AJ. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. Int J Infect Dis 2008;12(2):183–9. [15] Choconta-Piraquive LA, De la Hoz-Restrepo F, Sarmiento-Limas CA. Compliance with birth dose of Hepatitis B vaccine in high endemic and hard to reach areas in the Colombian amazon: results from a vaccination survey. BMC Health Serv Res 2016;16:293. [16] de la Hoz F, Perez L, Wheeler JG, de Neira M, Hall AJ. Vaccine coverage with hepatitis B and other vaccines in the Colombian Amazon: do health worker knowledge and perception influence coverage? Trop Med Int Health 2005;10 (4):322–9. [17] Devesa M, Loureiro CL, Rivas Y, Monsalve F, Cardona N, Duarte MC, et al. Subgenotype diversity of hepatitis B virus American genotype F in Amerindians from Venezuela and the general population of Colombia. J Med Virol 2008;80:20–6. [18] Ximenes RA, Figueiredo GM, Cardoso MR, Stein AT, Moreira RC, Coral G, et al. Population-based multicentric survey of hepatitis B infection and risk factors in the north, south, and southeast regions of Brazil, 10–20 years after the beginning of vaccination. Am J Trop Med Hyg 2015;93(6):1341–8. [19] Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212–9. [20] Luna EJ, Veras MA, Flannery B, de Moraes JC, Vaccine Coverage Survey 2007 Group. Household survey of hepatitis B vaccine coverage among Brazilian children. Vaccine 2009;27(39):5326–31. [21] Shrestha AC, Ghimire P, Tiwari BR, Rajkarnikar M. Transfusion-transmissible infections among blood donors in Kathmandu, Nepal. J Infect Dev Ctries 2009;3(10):794–7. [22] Chander A, Pahwa VK. Status of infectious disease markers among blood donors in a teaching hospital, Bhairahawa, western Nepal. J Commun Dis 2003;35(3):188–97. [23] Karki S, Ghimire P, Tiwari BR, Maharjan A, Rajkarnikar M. Trends in hepatitis B and hepatitis C seroprevalence among Nepalese blood donors. Jpn J Infect Dis 2008;61(4):324–6. [24] Tiwari BR, Ghimire P, Kandel SR, Rajkarnikar M. Seroprevalence of HBV and HCV in blood donors: a study from regional blood transfusion services of Nepal. Asian J Transfus Sci 2010;4(2):91–3. [25] Bidya S. HBsAg carriers among healthy Nepalese men: a serological survey. J Health Popul Nutr 2002;20(3):235–8. [26] Henderson A, Bowler AJ. Hepatitis B surface antigen carriage in healthy Nepalese men. Trans R Soc Trop Med Hyg 1987;81(5):875. [27] Joshi SK, Ghimire GR. Serological prevalence of antibodies to human immunodeficiency virus (HIV) and hepatitis B virus (HBV) among healthy Nepalese males – a retrospective study. Kathmandu Univ Med J (KUMJ) 2003;1 (4):251–5.
dc.rights.spa.fl_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
http://creativecommons.org/licenses/by-nc-sa/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.publisher.spa.fl_str_mv Universidad de la Costa
institution Corporación Universidad de la Costa
bitstream.url.fl_str_mv https://repositorio.cuc.edu.co/bitstreams/8a9e3156-2d01-4d7f-96e0-1323c10fd9c4/download
https://repositorio.cuc.edu.co/bitstreams/4c672e54-2bfb-4423-850b-bcd11fbabcad/download
https://repositorio.cuc.edu.co/bitstreams/43f9c325-82ac-425b-bd40-f6385f11e80f/download
https://repositorio.cuc.edu.co/bitstreams/b9a165fd-d1a7-4bdb-8e53-7ecaa8246dc0/download
https://repositorio.cuc.edu.co/bitstreams/3ef897a8-28a2-4f30-b118-3867defb581b/download
bitstream.checksum.fl_str_mv cc9a16ea11b8b269b409b902696b5f22
934f4ca17e109e0a05eaeaba504d7ce4
8a4605be74aa9ea9d79846c1fba20a33
714c633e1b3c9f98a806ab3837be39ae
113cab3a857c2615ed025f91d8d33bd2
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio de la Universidad de la Costa CUC
repository.mail.fl_str_mv repdigital@cuc.edu.co
_version_ 1811760834630647808
spelling Garcia, DiegoPorras, AlexandraRico Mendoza, AlejadroAlvis, NelsonCristina Navas, MariaDe La Hoz, FernandoDe Neira, MarlenOsorio, ElkinFernando Valderrama, José2019-05-27T14:12:24Z2019-05-27T14:12:24Z2017-11-05https://hdl.handle.net/11323/4718Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Background: Hepatitis B virus (HBV) infection is highly endemic in the Colombian Amazon basin. In Colombia, the universal hepatitis B vaccination in that area has been active since 1993. The program targets children aged under five years. Newborns receive at least three doses, and in 2001, HBV vaccine birth dose was included. This study aimed to evaluate the advances on HBV control in the Colombian Amazon. Methods: A population-based cross-sectional study was conducted in children less than 11 years old in rural areas of the Colombian Amazon, in order to assess the current levels of HBV prevalence and evaluate the effectiveness of HBV vaccination. Participants were selected from villages scattered along the Amazon, Putumayo and Loretoyaco Rivers. Blood samples were taken from children. All the samples were examined for surface antigen (HBsAg) and IgG antibodies against core antigen (AntiHBc) of HBV. Data on HBV vaccination status and other risk factors were also collected. Results: Blood samples from 1275 children were included in the study. The positivity for IgG AntiHBC and HBsAg was 3.8% and 0.5%, respectively. It was observed that receiving a dose of HBV vaccine within 48 h after birth decreased the risk of HBV infection and carriage by 95%. Being born to an AntiHBc positive mother increased 8 times the risk of HBV infection (OR = 7.8 CI 95% 3.3–10.2) and 7 times the risk of HBsAg carriage (OR = 6.6 CI 95% 2.1–10.1). Conclusion: The prevalence of HBV infection and HBsAg carriage continues to decrease among children living in the Colombian Amazon. The high protective effectiveness of an HBV birth does suggest that perinatal transmission is important in endemic areas of Latin America, an aspect that has not been fully studied in the region.Antecedentes: la infección por el virus de la hepatitis B (VHB) es altamente endémica en la cuenca amazónica colombiana. En Colombia, la vacuna universal contra la hepatitis B en esa área ha estado activa desde 1993. El programa está dirigido a niños menores de cinco años. Los recién nacidos reciben al menos tres dosis y, en 2001, se incluyó la dosis de nacimiento de la vacuna contra el VHB. Este estudio tuvo como objetivo evaluar los avances en el control del VHB en la Amazonía colombiana. Métodos: se realizó un estudio transversal basado en la población en niños menores de 11 años en áreas rurales de la Amazonía colombiana, para evaluar los niveles actuales de prevalencia del VHB y evaluar la efectividad de la vacunación contra el VHB. Los participantes fueron seleccionados de aldeas dispersas a lo largo de los ríos Amazonas, Putumayo y Loretoyaco. Se tomaron muestras de sangre de niños. Todas las muestras se examinaron para determinar el antígeno de superficie (HBsAg) y los anticuerpos IgG contra el antígeno del núcleo (AntiHBc) del VHB. También se recogieron datos sobre el estado de vacunación contra el VHB y otros factores de riesgo. Resultados: Se incluyeron muestras de sangre de 1275 niños en el estudio. La positividad para IgG AntiHBC y HBsAg fue de 3.8% y 0.5%, respectivamente. Se observó que recibir una dosis de la vacuna contra el VHB dentro de las 48 h posteriores al nacimiento disminuyó el riesgo de infección y transporte por VHB en un 95%. El hecho de nacer de una madre con AntiHBc positivo aumentó 8 veces el riesgo de infección por VHB (OR = 7,8 IC 95% 3.3–10.2) y 7 veces el riesgo de portar HBsAg (OR = 6.6 IC 95% 2.1–10.1). Conclusión: la prevalencia de la infección por VHB y el transporte de HBsAg continúa disminuyendo entre los niños que viven en la Amazonía colombiana. La alta efectividad protectora de un parto por VHB sugiere que la transmisión perinatal es importante en áreas endémicas de América Latina, un aspecto que no se ha estudiado completamente en la región.Garcia, Diego-eb0ade1b-57e7-43cf-bab4-3a6acab81ce1-0Porras, Alexandra-02fb0db8-26a0-4397-8f73-ef6a5c0e9868-0Rico Mendoza, Alejadro-a70cadc6-ddd7-4a7a-9a40-e90ebc19d10a-0Alvis, Nelson-0c58fd8c-9cd2-4000-bbc8-ca71c6389ff3-0Cristina Navas, Maria-8b27bee1-6a8d-45b6-89f8-188466d8ed27-0De La Hoz, Fernando-026bd043-20eb-4a68-bf63-440e81dd019d-0De Neira, Marlen-15894815-69e4-442d-8fbd-033d54a23d7b-0Osorio, Elkin-db2ba15d-088d-4d31-9307-a4b7ffd912c6-0Fernando Valderrama, José-1e19a4af-4729-468b-bc28-fc082fde4788-0engUniversidad de la CostaAttribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Hepatitis BPrevalenceEffectiveness of HBV birth doseColombiaPredominioEficacia de la dosis de nacimiento del VHBHepatitis B infection control in Colombian amazonControl de la infección por hepatitis B en la amazonia colombiana.Artículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/acceptedVersion[1] Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386 (10003):1546–55. [2] Díez-Padrisa N, Castellanos LG, PAHO Viral Hepatitis Working Group. Viral hepatitis in Latin America and the Caribbean: a public health challenge. Rev Panam Salud Publica 2013;34(4):275–81. [3] Bensabath G, Hadler SC, Soares MC, Fields H, Dias LB, Popper H, et al. Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin. JAMA 1987;258(4):479–83. [4] Cabezas-Sánchez C, Trujillo-Villarroel O, Zavaleta-Cortijo C, Culqui-Lévano D, Suarez-Jara M, Cueva-Maza N, et al. Prevalencia de la infección por el virus de hepatitis B en niños menores de 5 años de comunidades indígenas de la Amazonía peruana posterior a intervenciones mediante inmunización. Rev Perú med exp salud publica 2014;31(2):204–10. Available in: <http://www. scielo.org.pe/scielo.php?pid=S1726-46342014000200003&script=sci_arttext> [Consulted in March 17, 2017]. [5] Martínez M, De La Hoz F. Estudio de seroprevalencia y factores de riesgo de infección con el virus de la hepatitis B en los ribereños del río Putumayo, Colombia, 1990–1991. Biomedica 1994;14(suppl 1):51. [6] Van Damme P. Long-term protection after hepatitis B vaccine. J Infect Dis 2016;214(1):1–3. [7] Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986–90) and in the nationwide immunization program. BMC Infect Dis 2014;14:7. [8] Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 2012;16(2):e82–8. [9] Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China. J Infect Dis 2009;200(1):39–47. [10] Wilson N, Ruff TA, Rana BJ, Leydon J, Locarnini S. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu. Vaccine 2000;18(26):3059–66. [11] World Health Organization. WHO guidelines on hand hygiene in health care. Ginebra: World Health Organization; 2009. Available in: <http://apps.who.int/ iris/bitstream/10665/44102/1/9789241597906_eng.pdf> [Consulted: March 17, 2017]. [12] Ropero AM, Danovaro-Holliday MC, Andrus JK. Progress in vaccination against hepatitis B in the Americas. J Clin Virol 2005;34(suppl 2):S14–9. [13] Braga WS, Castilho Mda C, Borges FG, Martinho AC, Rodrigues IS, Azevedo EP, et al. Prevalence of hepatitis B virus infection and carriage after nineteen years of vaccination program in the Western Brazilian Amazon. Rev Soc Bras Med Trop 2012;45(1):13–7. [14] de la Hoz F, Perez L, de Neira M, Hall AJ. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. Int J Infect Dis 2008;12(2):183–9. [15] Choconta-Piraquive LA, De la Hoz-Restrepo F, Sarmiento-Limas CA. Compliance with birth dose of Hepatitis B vaccine in high endemic and hard to reach areas in the Colombian amazon: results from a vaccination survey. BMC Health Serv Res 2016;16:293. [16] de la Hoz F, Perez L, Wheeler JG, de Neira M, Hall AJ. Vaccine coverage with hepatitis B and other vaccines in the Colombian Amazon: do health worker knowledge and perception influence coverage? Trop Med Int Health 2005;10 (4):322–9. [17] Devesa M, Loureiro CL, Rivas Y, Monsalve F, Cardona N, Duarte MC, et al. Subgenotype diversity of hepatitis B virus American genotype F in Amerindians from Venezuela and the general population of Colombia. J Med Virol 2008;80:20–6. [18] Ximenes RA, Figueiredo GM, Cardoso MR, Stein AT, Moreira RC, Coral G, et al. Population-based multicentric survey of hepatitis B infection and risk factors in the north, south, and southeast regions of Brazil, 10–20 years after the beginning of vaccination. Am J Trop Med Hyg 2015;93(6):1341–8. [19] Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212–9. [20] Luna EJ, Veras MA, Flannery B, de Moraes JC, Vaccine Coverage Survey 2007 Group. Household survey of hepatitis B vaccine coverage among Brazilian children. Vaccine 2009;27(39):5326–31. [21] Shrestha AC, Ghimire P, Tiwari BR, Rajkarnikar M. Transfusion-transmissible infections among blood donors in Kathmandu, Nepal. J Infect Dev Ctries 2009;3(10):794–7. [22] Chander A, Pahwa VK. Status of infectious disease markers among blood donors in a teaching hospital, Bhairahawa, western Nepal. J Commun Dis 2003;35(3):188–97. [23] Karki S, Ghimire P, Tiwari BR, Maharjan A, Rajkarnikar M. Trends in hepatitis B and hepatitis C seroprevalence among Nepalese blood donors. Jpn J Infect Dis 2008;61(4):324–6. [24] Tiwari BR, Ghimire P, Kandel SR, Rajkarnikar M. Seroprevalence of HBV and HCV in blood donors: a study from regional blood transfusion services of Nepal. Asian J Transfus Sci 2010;4(2):91–3. [25] Bidya S. HBsAg carriers among healthy Nepalese men: a serological survey. J Health Popul Nutr 2002;20(3):235–8. [26] Henderson A, Bowler AJ. Hepatitis B surface antigen carriage in healthy Nepalese men. Trans R Soc Trop Med Hyg 1987;81(5):875. [27] Joshi SK, Ghimire GR. Serological prevalence of antibodies to human immunodeficiency virus (HIV) and hepatitis B virus (HBV) among healthy Nepalese males – a retrospective study. Kathmandu Univ Med J (KUMJ) 2003;1 (4):251–5.PublicationORIGINALHEPATITIS B INFECTION CONTROL IN COLOMBIAN AMAZON.pdfHEPATITIS B INFECTION CONTROL IN COLOMBIAN AMAZON.pdfapplication/pdf110287https://repositorio.cuc.edu.co/bitstreams/8a9e3156-2d01-4d7f-96e0-1323c10fd9c4/downloadcc9a16ea11b8b269b409b902696b5f22MD52CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81031https://repositorio.cuc.edu.co/bitstreams/4c672e54-2bfb-4423-850b-bcd11fbabcad/download934f4ca17e109e0a05eaeaba504d7ce4MD53LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.cuc.edu.co/bitstreams/43f9c325-82ac-425b-bd40-f6385f11e80f/download8a4605be74aa9ea9d79846c1fba20a33MD54THUMBNAILHEPATITIS B INFECTION CONTROL IN COLOMBIAN AMAZON.pdf.jpgHEPATITIS B INFECTION CONTROL IN COLOMBIAN AMAZON.pdf.jpgimage/jpeg64310https://repositorio.cuc.edu.co/bitstreams/b9a165fd-d1a7-4bdb-8e53-7ecaa8246dc0/download714c633e1b3c9f98a806ab3837be39aeMD56TEXTHEPATITIS B INFECTION CONTROL IN COLOMBIAN AMAZON.pdf.txtHEPATITIS B INFECTION CONTROL IN COLOMBIAN AMAZON.pdf.txttext/plain2131https://repositorio.cuc.edu.co/bitstreams/3ef897a8-28a2-4f30-b118-3867defb581b/download113cab3a857c2615ed025f91d8d33bd2MD5711323/4718oai:repositorio.cuc.edu.co:11323/47182024-09-17 14:07:47.329http://creativecommons.org/licenses/by-nc-sa/4.0/Attribution-NonCommercial-ShareAlike 4.0 Internationalopen.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.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

Publicaciones similares